Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma. Han F, Zhong Y, Tong C, Wang C, et al. Am J Hematol 2026 Mar 9. doi: 10.1002/ajh.70281.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Han F, Zhong Y, Tong C, Wang C, et al. Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma. Am J Hematol 2026 Mar 9. doi: 10.1002/ajh.70281.
PMID: 41804087